Colchicine is safe and effective for secondary prevention of recurrent pericarditis
- 458 Downloads
Recurrence is the most common complication of acute pericarditis, occurring in 10–30 % of patients with a first episode, and again in up to 50 % after a first recurrence of acute pericarditis .
Observational studies [2, 3, 4] and an open-label, single-center, randomized trial  show that colchicine can significantly reduce pericarditis recurrence rate. On the basis of these data, colchicine is recommended in the European Society of Cardiology guidelines (level of evidence B, class IIa indication) for the initial attack as well as the prevention of recurrences of acute pericarditis .
However, no multicenter, double-blind, randomized trial has confirmed these favorable findings.
The CORP (COlchicine for Recurrent Pericarditis) trial  is a prospective, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of colchicine (1.0–2.0 mg on the first day, followed by a maintenance dose of 0.5–1.0 mg/day for 6 months) in...
KeywordsColchicine Pericarditis Relative Risk Reduction Cardiac Tamponade Absolute Risk Reduction
Conflict of interest
- 6.Maisch B, Seferovic PM, Ristic AD et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary. Eur Heart J 6(10):1046–1047Google Scholar
- 8.Imazio M, Cecchi E, Ierna S, Trinchero R, ICAP Investigators (2007) Investigation on colchicine for acute pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design and rationale. J Cardiovasc Med (Hagerstown) 8:613–617CrossRefGoogle Scholar